Peribulbar Corticosteroids for Ocular Myasthenia Gravis

Rachel Lasry, Marc Gotkine, Joshua M. Kruger*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Ocular myasthenia gravis is treated predominantly by oral medications, with the potential for systemic adverse effects. Successful treatment has been achieved using peribulbar dexamethasone. We assessed the effect of peribulbar dexamethasone or triamcinolone (40-mg Triesence), a longer-acting corticosteroid, targeting the peribulbar area as opposed to directly injecting the affected extraocular muscle. This more convenient and secure approach holds the potential for straightforward integration within clinical environments. Methods: Retrospective chart review. Results: Five patients were identified that were treated with peribulbar corticosteroids. In 4 of the 5 cases, ophthalmoparesis was unilateral. One case had isolated ptosis, and 4 had both ptosis and ophthalmoparesis. Three of these 4 cases reported complete resolution of symptoms within weeks of a single injection. Improvement lasted between 5 to 6 months, and all patients responded to repeated injections. Conclusions: Peribulbar corticosteroids can be effective in ocular myasthenia gravis. We suggest that longer-acting agents such as triamcinolone are preferable, to reduce injection frequency.

Original languageEnglish
Pages (from-to)419-422
Number of pages4
JournalJournal of Neuro-Ophthalmology
Volume44
Issue number3
DOIs
StatePublished - 1 Sep 2024
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2024 by North American Neuro-Ophthalmology Society.

Fingerprint

Dive into the research topics of 'Peribulbar Corticosteroids for Ocular Myasthenia Gravis'. Together they form a unique fingerprint.

Cite this